Closely watched experimental Parkinson’s drug fails key clinical trial
statnews.com • • business
Key Points:
- Biogen and Denali Therapeutics announced that their experimental Parkinson’s disease therapy failed to slow the progression of the disorder in a randomized clinical trial involving 648 participants.
- The therapy targeted the LRRK2 protein, linked to a rare inherited form of Parkinson’s discovered in 2004, and was hypothesized to benefit all Parkinson’s patients.
- The trial results represent a major setback for the scientific approach of blocking LRRK2 as a treatment strategy for Parkinson’s disease.
- This outcome challenges previous optimism and research suggesting that inhibiting LRRK2 could slow disease progression in a broader patient population.